Beyond the insurance rally, corporate activity remains robust across global pharmaceutical markets. European regulators have cleared a path for Sanofi, accepting the drugmaker’s concessions to resolve an antitrust probe regarding its flu vaccine marketing strategies. Meanwhile, the dermatology sector saw a significant consolidation as Swiss firm Galderma moved to acquire ZO Skin Health from Blackstone and the Obagi family in a deal valued at $1.5 billion.

In Switzerland, Lonza Group reaffirmed its annual growth targets while emphasizing a pivot toward stricter cost controls. Simultaneously, the IPO market faces a fresh test in Southeast Asia, where Malaysia’s Big Caring pharmacy chain prepares to launch a public offering seeking $600 million. This move seeks to gauge investor sentiment despite the prevailing volatility across global exchanges.